Chemical formula: C₁₄H₁₂N₆O Molecular mass: 280.285 g/mol PubChem compound: 3033825
Levosimendan enhances the calcium sensitivity of contractile proteins by binding to cardiac troponin C in a calcium-dependent manner. Levosimendan increases the contraction force but does not impair ventricular relaxation.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C01CX08 | Levosimendan | C Cardiovascular system → C01 Cardiac therapy → C01C Cardiac stimulants excl. cardiac glycosides → C01CX Other cardiac stimulants |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| SIMDAX Injection | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC |
Levosimendan is an active ingredient of these brands:
Brazil (BR)Croatia (HR)Cyprus (CY)Estonia (EE)Finland (FI)France (FR)Hong Kong (HK)Israel (IL)Lithuania (LT)Mexico (MX)New Zealand (NZ)Poland (PL)Romania (RO)Spain (ES)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
